Skip to content
mapperlab
← Dashboard
Stock

EXEL

EXELIXIS, INC.
Health CareBiotechnologyLatest close $507 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
9
Current + past
New this quarter
0
Exited this quarter
1

Marquee-fund ownership over time

Aug 14, 2017Nov 12, 2021Aug 9, 2024May 15, 2026
Now
7

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Bridgewater Associates re-entered$18$50+173%
Renaissance Technologies$27$50+85%
Citadel Advisors re-entered$26$50+90%
Two Sigma Investments$26$50+90%
D.E. Shaw$26$50+90%
AQR Capital Management$26$50+90%
Millennium Management$26$50+90%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Point72 Asset Management→ $50+14%
Maverick Capital 3× in & out→ $19-26%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at EXELIXIS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
23
Filings · last 90d
23
Total on file
638
Recent SEC buffer
Most recent
Jun 3, 2026

30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 638 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · EXELIXIS, INC.

Annual figures sourced directly from EXELIXIS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$2.32B
FY2026+7% YoY
Net income
$782.57M
FY2026+50% YoY
EPS (diluted)
$2.78
FY2026+58% YoY
Free cash flow(?)
$875.84M
FY2026+30% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for EXELIXIS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ1 2026Q2 2026$44$50+14%
Citadel AdvisorsQ3 2025open$38$50+30%
Bridgewater AssociatesQ2 2025open$45$48+9%
Citadel AdvisorsQ3 2024Q2 2025$26$46+76%
Two Sigma InvestmentsQ3 2024open$26$50+90%
D.E. ShawQ3 2024open$26$50+90%
AQR Capital ManagementQ3 2024open$26$50+90%
Millennium ManagementQ3 2024open$26$50+90%
Renaissance TechnologiesQ3 2024open$27$50+85%
Bridgewater AssociatesQ1 2023Q2 2023$18$19+8%
Bridgewater AssociatesQ2 2022Q4 2022$20$17-16%
Bridgewater AssociatesQ3 2021Q4 2021$18$18-1%
Maverick CapitalQ2 2021Q1 2022$25$19-26%
Maverick CapitalQ4 2019Q2 2020$17$26+55%
Maverick CapitalQ3 2017Q4 2017$27$25-6%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.